Selected Immunicum-related Posters & Publications
Rizell et al. Phase I Trial with the Cell-Based Immune Primer Ilixadencel, Alone and Combined with Sorafenib, in Advanced Hepatocellular Carcinoma. Front Oncol 2019
(link to journal)
Karlsson-Parra et al. Intratumoral administration of pro-inflammatory allogeneic, off-the-shelf, dendritic cells in combination with anti-PD-1 or anti-CD137 has a synergistic anti-tumor effect. European Society for Medical Oncology (ESMO) Congress 2018
(link to pdf)
Karlsson-Parra et al. Ilixadencel – an Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration. Pharm Res 2018 (link to PubMed)
Rizell et al. Combination treatment of immune primer ilixadencel with standard therapy known to inhibit immunosuppression: a case report. Cholangiocarcinoma Foundation Annual Conference 2018 (link to pdf)
Fotaki et al. Cancer vaccine based on a combination of an infection-enhanced adenoviral vector and pro-inflammatory allogeneic DCs leads to sustained antigen-specific immune responses in three melanoma models. Oncoimmunology 2017 (link to PubMed)
Fotaki et al. Pro-inflammatory allogeneic DCs promote activation of bystander immune cells and thereby license antigen-specific T-cell responses. Oncoimmunology 2017 (link to PubMed)
Fotaki et al. In vitro mode of action of ilixadencel – a cell-based allogeneic immune primer for intratumoral administration. Society for Immunotherapy of Cancer (SITC) Annual Meeting 2018 (link to pdf)
Laurell et al. Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma. J Immunother Cancer 2017 (link to PubMed)
Selected Publications supporting Immunicums ilixadencel approach
Böttcher et al. NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control. Cell 2018 (link to PubMed).
Take home message: Activated NK cells and chemokines within the tumor are crucial to recruitment and activation of immature DCs, and the interplay between NK cells, chemokines and DCs is important in cancer immune control.
Pang et al. IL-1R signaling in dendritic cells replaces pattern-recognition receptors in promoting CD8(+) T cell responses to influenza A virus. Nat Immunol 2013 (link to PubMed).
Take home message: Proof of concept study in sophisticated mouse models showing that DCs infected with a influenza virus in vivo become disabled as antigen-presenting cells but induce maturation of bystander, non-infected, DCs that subsequently primes antigen-specific cytotoxic CD8+ T cells.
Pascutti et al. Interplay between modified vaccinia virus Ankara and dendritic cells: phenotypic and functional maturation of bystander dendritic cells. J Virol 2011 (link to PubMed).
Take home message: DCs directly infected with a vaccinia virus in vitro become disabled as antigen-presenting cells but induce maturation of bystander, non-infected, DCs.
Yewdall et al. CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells. PLoS One 2010 (link to PubMed).
Take home message: The direct priming of CD8+ T cells after vaccination with antigen-loaded DCs is mainly performed by endogenous DCs and not by the administered DCs.
Gustafsson et al. Recruitment and activation of natural killer cells in vitro by a human dendritic cell vaccine. Cancer Res 2008 (link to PubMed).
Take home message: Activation of human monocyte-derived DCs with a combination of a TLR-ligand and IFN-gamma induces a vigorous and sustained production of NK-cell recruiting and NK-cell activating factors.
Wallgren et al. Direct allorecognition promotes activation of bystander dendritic cells and licenses them for Th1 priming: a functional link between direct and indirect allosensitization. Scand J Immunol 2005 (link to PubMed).
Take home message: The rejection of allogeneic dendritic cells in vitro induces production of DC-recruiting and DC activation factors.